Novo Nordisk A/S
Bagsværd, Denmark, 5 February 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name of the Board member/Executive/Associated Person
Liselotte Sofie Hyveled
2
Reason for the notification
a)
Position/status
Member of the Board of Directors
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer
a)
Name
Novo Nordisk A/S
b)
LEI
549300DAQ1CVT6CXN342
4
Details of the transaction(s)
a)
Description of the financial instrument,
type of instrument,
Shares
Identification code
Novo Nordisk B DK0062498333
b)
Nature of the transaction
Other transaction (transfer of shares in
accordance with Long Term Incentive programme)
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 0.00
1,085
d)
Aggregated information
1,085 shares
DKK 0.00
e)
Date of the transaction
2026-02-04
f)
Place of the transaction
Outside a trading venue
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name of the Board member/Executive/Associated Person
Maziar Mike Doustdar
2
Reason for the notification
a)
Position/status
President and CEO
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer
a)
Name
Novo Nordisk A/S
b)
LEI
549300DAQ1CVT6CXN342
4
Details of the transaction(s)
a)
Description of the financial instrument,
type of instrument,
Shares
Identification code
Novo Nordisk B DK0062498333
b)
Nature of the transaction
Other transaction (transfer of shares in
accordance with Long Term Incentive programme)
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 0.00
28,049
d)
Aggregated information
28,049 shares
DKK 0.00
e)
Date of the transaction
2026-02-04
f)
Place of the transaction
Outside a trading venue
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name of the Board member/Executive/Associated Person
David Moore
2
Reason for the notification
a)
Position/status
Executive Vice President, US Operations
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer
a)
Name
Novo Nordisk A/S
b)
LEI
549300DAQ1CVT6CXN342
4
Details of the transaction(s)
a)
Description of the financial instrument,
type of instrument,
Shares
Identification code
Novo Nordisk B DK0062498333
b)
Nature of the transaction
Other transaction (transfer of shares in
accordance with Long Term Incentive programme)
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 0.00
23,895
d)
Aggregated information
23,895 shares
DKK 0.00
e)
Date of the transaction
2026-02-04
f)
Place of the transaction
Outside a trading venue
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name of the Board member/Executive/Associated Person
David Moore
2
Reason for the notification
a)
Position/status
Executive Vice President, US Operations
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer
a)
Name
Novo Nordisk A/S
b)
LEI
549300DAQ1CVT6CXN342
4
Details of the transaction(s)
a)
Description of the financial instrument,
type of instrument,
Shares
Identification code
Novo Nordisk B DK0062498333
b)
Nature of the transaction
Sale of shares (to cover tax on shares transferred in accordance with Long Term Incentive programme)
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 304.72
6,845
d)
Aggregated information
6,845 shares
DKK 2,085,839.07
e)
Date of the transaction
2026-02-04
f)
Place of the transaction
Nasdaq Copenhagen
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name of the Board member/Executive/Associated Person
Emil Kongshøj Larsen
2
Reason for the notification
a)
Position/status
Executive Vice President, International Operations
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer
a)
Name
Novo Nordisk A/S
b)
LEI
549300DAQ1CVT6CXN342
4
Details of the transaction(s)
a)
Description of the financial instrument,
type of instrument,
Shares
Identification code
Novo Nordisk B DK0062498333
b)
Nature of the transaction
Other transaction (transfer of shares in
accordance with Long Term Incentive programme)
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 0.00
7,289
d)
Aggregated information
7,289 shares
DKK 0.00
e)
Date of the transaction
2026-02-04
f)
Place of the transaction
Outside a trading venue
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name of the Board member/Executive/Associated Person
Emil Kongshøj Larsen
2
Reason for the notification
a)
Position/status
Executive Vice President, International Operations
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer
a)
Name
Novo Nordisk A/S
b)
LEI
549300DAQ1CVT6CXN342
4
Details of the transaction(s)
a)
Description of the financial instrument,
type of instrument,
Shares
Identification code
Novo Nordisk B DK0062498333
b)
Nature of the transaction
Sale of shares (to cover taxes transferred in accordance with Long Term Incentive programme)
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 304.72
3,645
d)
Aggregated information
3,645 shares
DKK 1,110,720.73
e)
Date of the transaction
2026-02-04
f)
Place of the transaction
Nasdaq Copenhagen
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name of the Board member/Executive/Associated Person
Tania Sabroe
2
Reason for the notification
a)
Position/status
Executive Vice President, People, Organisation & Corporate Affairs
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer
a)
Name
Novo Nordisk A/S
b)
LEI
549300DAQ1CVT6CXN342
4
Details of the transaction(s)
a)
Description of the financial instrument,
type of instrument,
Shares
Identification code
Novo Nordisk B DK0062498333
b)
Nature of the transaction
Other transaction (transfer of shares in
accordance with Long Term Incentive programme)
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 0.00
11,562
d)
Aggregated information
11,562 shares
DKK 0.00
e)
Date of the transaction
2026-02-04
f)
Place of the transaction
Outside a trading venue
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name of the Board member/Executive/Associated Person
Martin Holst Lange
2
Reason for the notification
a)
Position/status
Executive Vice President, R&D and Chief Scientific Officer (CSO)
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer
a)
Name
Novo Nordisk A/S
b)
LEI
549300DAQ1CVT6CXN342
4
Details of the transaction(s)
a)
Description of the financial instrument,
type of instrument,
Shares
Identification code
Novo Nordisk B DK0062498333
b)
Nature of the transaction
Other transaction (transfer of shares in
accordance with Long Term Incentive programme)
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 0.00
23,092
d)
Aggregated information
23,092 shares
DKK 0.00
e)
Date of the transaction
2026-02-04
f)
Place of the transaction
Outside a trading venue
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name of the Board member/Executive/Associated Person
Thilde Hummel Bøgebjerg
2
Reason for the notification
a)
Position/status
Executive Vice President, Enterprise IT & Quality
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer
a)
Name
Novo Nordisk A/S
b)
LEI
549300DAQ1CVT6CXN342
4
Details of the transaction(s)
a)
Description of the financial instrument,
type of instrument,
Shares
Identification code
Novo Nordisk B DK0062498333
b)
Nature of the transaction
Other transaction (transfer of shares in
accordance with Long Term Incentive programme)
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 0.00
5,009
d)
Aggregated information
5,009 shares
DKK 0.00
e)
Date of the transaction
2026-02-04
f)
Place of the transaction
Outside a trading venue
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name of the Board member/Executive/Associated Person
Karsten Munk Knudsen
2
Reason for the notification
a)
Position/status
Executive Vice President, Chief Financial Officer (CFO)
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer
a)
Name
Novo Nordisk A/S
b)
LEI
549300DAQ1CVT6CXN342
4
Details of the transaction(s)
a)
Description of the financial instrument,
type of instrument,
Shares
Identification code
Novo Nordisk B DK0062498333
b)
Nature of the transaction
Other transaction (transfer of shares in
accordance with Long Term Incentive programme)
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 0.00
26,557
d)
Aggregated information
26,557 shares
DKK 0.00
e)
Date of the transaction
2026-02-04
f)
Place of the transaction
Outside a trading venue
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name of the Board member/Executive/Associated Person
Kasper Bødker Mejlvang
2
Reason for the notification
a)
Position/status
Executive Vice President, CMC & Product Supply
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer
a)
Name
Novo Nordisk A/S
b)
LEI
549300DAQ1CVT6CXN342
4
Details of the transaction(s)
a)
Description of the financial instrument,
type of instrument,
Shares
Identification code
Novo Nordisk B DK0062498333
b)
Nature of the transaction
Other transaction (transfer of shares in
accordance with Long Term Incentive programme)
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 0.00
6,706
d)
Aggregated information
6,706 shares
DKK 0.00
e)
Date of the transaction
2026-02-04
f)
Place of the transaction
Outside a trading venue
1
Details of the person discharging managerial responsibilities/person closely associated
a)
Name of the Board member/Executive/Associated Person
Ludovic Helfgott
2
Reason for the notification
a)
Position/status
Executive Vice President, Product & Portfolio Strategy
b)
Initial notification/Amendment
Initial notification
3
Details of the issuer
a)
Name
Novo Nordisk A/S
b)
LEI
549300DAQ1CVT6CXN342
4
Details of the transaction(s)
a)
Description of the financial instrument,
type of instrument,
Shares
Identification code
Novo Nordisk B DK0062498333
b)
Nature of the transaction
Other transaction (transfer of shares in
accordance with Long Term Incentive programme)
c)
Price(s) and volume(s)
Price(s)
Volume(s)
DKK 0.00
21,075
d)
Aggregated information
21,075 shares
DKK 0.00
e)
Date of the transaction
2026-02-04
f)
Place of the transaction
Outside a trading venue
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.